Cure8 research brief
The study tests a novel cell‑based way to deliver the anti‑inflammatory cytokine IL‑10 directly to the gut using engineered macrophages, which reduced disease signs in a mouse colitis model and altered the gut microbiome. This could point toward new therapeutic strategies for UC, but it remains preclinical.
Researchers in IBD immunology and cell therapy; clinicians tracking preclinical therapy advances; translational scientists focused on microbiome–immune interactions.
The authors created IL‑10‑secreting macrophages from a RAW264.7 cell line and gave them intraperitoneally to mice with dextran sulfate sodium (DSS)‑induced colitis. Treated mice had less weight loss, lower disease scores, less colon shortening, improved histology and epithelial barrier markers, and shifts in gut bacterial composition.
Flow cytometry detected GFP+ engineered macrophages in colonic tissue and an early rise in CD206+ endogenous macrophages. Short‑term safety checks reported no major blood, liver, or spleen abnormalities in this model. This is an experimental preclinical study in mice (abstract level).
It shows proof‑of‑concept for a macrophage cell therapy delivering IL‑10 and reports associated microbiome changes, but it does not provide evidence about safety or effectiveness in humans.
Findings come from a DSS mouse model using engineered RAW264.7 macrophages and are at the preclinical stage. Human relevance, long‑term safety, and clinical delivery methods are not addressed in this report.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This preclinical study describes a new cell‑based approach — macrophages engineered to secrete IL‑10 — that reduced inflammation and improved colon outcomes in a mouse colitis model, suggesting a potential avenue for...
The findings describe a novel cell‑based IL‑10 delivery strategy that reduced experimental colitis and altered gut microbiota—an approach that could inform future IBD therapies research.
If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...
